Benchmark analyst Josh Sullivan maintains Ultralife (NASDAQ:ULBI) with a Buy and raises the price target from $13 to $14.
- Headlines
- Benchmark Maintains Buy on Ultralife, Raises Price Target to $14
Benchmark Maintains Buy on Ultralife, Raises Price Target to $14
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
12:57
Since November, fund companies have collectively researched 701 listed companies.
CSI SWS Health Care index+2.05%
12:53
South Korea's president and South Korea's prime minister have canceled tomorrow's weekly meeting.
12:47
The Special Investigation Department of the South Korean Prosecutor's Office: Received many whistleblower letters regarding Yoon Suk-yeol, and a case has been filed for investigation.